Funding
← Back to your selection

Vivo Capital

Activity from announced rounds

Activity in this selectionUnited States · Jan 31, 2026 · Jan 1, 2026
Rounds participated in
2
Confirmed lead rounds
—
2 roles undisclosed
New companies
2
First participation on record · 0 follow-on
Funding in participating rounds
$210M
2 disclosed · full round size, not this investor’s share

By stage

Series B2

By primary sector

Biotech2

By country

United States2

Rounds

2 in this selection
EpiBiologics

Develops bispecific antibodies for targeted degradation of extracellular proteins.

$107MSeries B
Role not disclosed